These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25219824)

  • 21. [Study of gambogenic acid-induced apoptosis of melanoma B16 cells through PI3K/Akt/mTOR signaling pathways].
    Cheng H; Zhang X; Su JJ; Li QL
    Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1666-9. PubMed ID: 25095381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
    Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O; Wackwitz B; Haus U; Ortmann O
    Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.
    Trédan O; Treilleux I; Wang Q; Gane N; Pissaloux D; Bonnin N; Petit T; Cretin J; Bonichon-Lamichhane N; Priou F; Lavau-Denes S; Mari V; Freyer G; Lebrun D; Alexandre J; Ray-Coquard I
    Target Oncol; 2013 Dec; 8(4):243-51. PubMed ID: 23238879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
    Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
    J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN].
    Zhao LJ; Wei LH; Li XP; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):45-9. PubMed ID: 19563062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells.
    Block M; Fister S; Emons G; Seeber S; Gründker C; Günthert AR
    Anticancer Res; 2010 Jun; 30(6):2025-31. PubMed ID: 20651347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
    Cavazzoni A; Bonelli MA; Fumarola C; La Monica S; Airoud K; Bertoni R; Alfieri RR; Galetti M; Tramonti S; Galvani E; Harris AL; Martin LA; Andreis D; Bottini A; Generali D; Petronini PG
    Cancer Lett; 2012 Oct; 323(1):77-87. PubMed ID: 22484466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of insulin-like growth factor binding protein 2.
    Chao A; Lin CY; Wu RC; Lee YS; Lee LY; Tsai CL; Yang LY; Liu H; Chen SJ; Wang TH; Lai CH
    J Mol Med (Berl); 2018 Nov; 96(11):1251-1266. PubMed ID: 30298385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
    Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PTEN augments doxorubicin-induced apoptosis in PTEN-null Ishikawa cells.
    Wan X; Li J; Xie X; Lu W
    Int J Gynecol Cancer; 2007; 17(4):808-12. PubMed ID: 17359293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo and in vitro effects of RAD001 on bladder cancer.
    Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
    Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
    Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy Eve and Pac to induce apoptosis in cervical cancer cells by targeting PI3K/AKT/mTOR pathways.
    Dong P; Hao F; Dai S; Tian L
    J Recept Signal Transduct Res; 2018 Feb; 38(1):83-88. PubMed ID: 29369007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
    Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PI3K/AKT/mTOR signaling is involved in (-)-epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells.
    Liu S; Wang XJ; Liu Y; Cui YF
    Am J Chin Med; 2013; 41(3):629-42. PubMed ID: 23711146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.